By Mrinalika Roy and Patrick Wingrove (Reuters) -Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's new national priority voucher, suggesting it is a strong candidate for a significantly accelerated approval review. Lilly said it will submit its review package for the pill, orforglipron, to the FDA this quarter, adding the agency will decide on the approval process. In June, the FDA unveiled a program under which its commissioner ca ...